Sorafenib is a multikinase inhibitor that blocks tumor cell proliferation by inhibiting serine/threonine kinase isoforms of Raf, Raf-1, and B-Raf, leading to the inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) signaling pathways, decreased expression of cyclin D1 and cell cycle arrest. This evidence concerns the gene WNK2 and neoplasm.